Total Funding
20
36
Total FundingPost-IPO Debt raised
Growth Score
0 pts
Heat Score
-5 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
162987
Eiger is a biopharmaceutical company that develops new antiviral agents against novel targets in the treatment of hepatitis.
Curtis Scribner: Vice President, RegulatoryPast Role: RRD International, Senior Vice President for Medical and Regulatory Affairs- Colin Hislop: SVP Clinincal & Develoment OperationsPast Role: Anthera Pharmaceuticals, Senior Vice President and Chief Medical Officer
About the Company
Eiger BioPharmaceuticals is a privately held biotechnology company that develops a novel antiviral therapy for Hepatitis Delta, a life-threatening, Orphan Disease with high unmet medical need and no approved therapy. The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Its
strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients.
